- Home
- SPCB vs MAIA Comparison
SPCB vs MAIA Comparison
Compare SPCB & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPCB
- MAIA
- Stock Information
- Founded
- SPCB 1988
- MAIA 2018
- Country
- SPCB Israel
- MAIA United States
- Employees
- SPCB N/A
- MAIA N/A
- Industry
- SPCB Semiconductors
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- SPCB Technology
- MAIA Health Care
- Exchange
- SPCB Nasdaq
- MAIA Nasdaq
- Market Cap
- SPCB 53.3M
- MAIA 46.7M
- IPO Year
- SPCB N/A
- MAIA 2022
- Fundamental
- Price
- SPCB $10.55
- MAIA $1.74
- Analyst Decision
- SPCB Strong Buy
- MAIA
- Analyst Count
- SPCB 1
- MAIA 0
- Target Price
- SPCB $18.00
- MAIA N/A
- AVG Volume (30 Days)
- SPCB 190.1K
- MAIA 425.1K
- Earning Date
- SPCB 08-14-2025
- MAIA 08-08-2025
- Dividend Yield
- SPCB N/A
- MAIA N/A
- EPS Growth
- SPCB N/A
- MAIA N/A
- EPS
- SPCB 1.89
- MAIA N/A
- Revenue
- SPCB $27,831,000.00
- MAIA N/A
- Revenue This Year
- SPCB $2.73
- MAIA N/A
- Revenue Next Year
- SPCB $22.87
- MAIA N/A
- P/E Ratio
- SPCB $5.44
- MAIA N/A
- Revenue Growth
- SPCB 2.90
- MAIA N/A
- 52 Week Low
- SPCB $2.55
- MAIA $1.40
- 52 Week High
- SPCB $18.95
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- SPCB 55.51
- MAIA 47.75
- Support Level
- SPCB $9.66
- MAIA $1.66
- Resistance Level
- SPCB $11.14
- MAIA $1.95
- Average True Range (ATR)
- SPCB 0.89
- MAIA 0.12
- MACD
- SPCB -0.14
- MAIA -0.00
- Stochastic Oscillator
- SPCB 36.18
- MAIA 31.82
About SPCB SuperCom Ltd. (Israel)
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.